Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized immune monitoring could transform liver transplant care

NCT ID NCT06063213

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new method to monitor the immune system after a liver transplant. The goal is to see if a personalized approach can help doctors adjust immunosuppression drugs more accurately, reducing the risk of rejection or infection. Forty adult liver transplant recipients will be followed for six months to track episodes of rejection and infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phenotypic personalized medicine (PPM) protocol
What this could lead to
If successful, this could lead to a more personalized approach to managing immunosuppression after liver transplant, potentially reducing rejection and infection.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to all transplant patients. The approach is still being tested and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients that are simultaneous Liver Kidney Transplant recipients that are one month post transplant. Patients that are Liver Transplant recipients that are one month post transplant.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * At least one-month post-transplant * Recipient of a liver transplant alone or a simultaneous liver-kidney transplant Exclusion Criteria: * Unwilling to provide informed consent * Recipient of a previous bone marrow or stem cell transplant * Pregnant * Unlikely to be able to comply with the study requirements, as determined by the PI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transplant complication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease related to transplantation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transplant complication

Contacts and locations

Locations

  • University of Florida

    Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.